22 Sep 2017 11:05
Cathay International Holdings Limited
("Cathay" or the "Company")
Results of Special General Meeting ("SGM")
Hong Kong, 22 September 2017 - Cathay International Holdings Limited (LSE: CTI.L), an operator and investor in the growing healthcare sector in the People's Republic of China, today announces that at the SGM held earlier today, both resolutions as set out in the Notice of SGM dated 5 September 2017 were duly passed. The final poll voting results for each resolution are shown in the table below:
Ordinary resolutions | For | Against | Total votes | Withheld |
1. Re-election of Mr. Sum Soon Lim as Non-Executive Director | 396,849,764 | 41,954,520 | 438,804,284 | 13,256 |
2. Re-election of Mr. Kenneth K. Toong as Non-Executive Director | 396,849,764 | 41,954,520 | 438,804,284 | 13,256 |
Notes:
1. Any proxy votes which are at the discretion of the Chairman have been included in the 'For' total.
2. A vote 'Withheld' is not a vote in law and is not counted in the calculation of the proportion of the votes for and against a resolution.
A copy of the resolutions passed at the meeting is being uploaded today to the National Storage Mechanism and will shortly be available for viewing at www.morningstar.com.
The proxy figures for the resolutions will also be displayed on the Company website at www.cathay-intl.com.hk
- ENDS -
For further enquiries, please contact:
Cathay International Holdings Limited Eric Siu (Finance Director) Patrick Sung (Director and Controller)
|
Tel: +852 2828 9289 |
Consilium Strategic Communications Mary-Jane Elliott / Matthew Neal / Lindsey Neville
|
Tel: +44 (0) 203 709 5702
|
About Cathay
Cathay International Holdings Limited (LSE: CTI.L) is a main market listed investment holding company and an operator and investor in the growing healthcare sector in the People's Republic of China (the "PRC"). The Company and its subsidiaries (collectively the "Group") aim to leverage on growth opportunities in the strong and growing domestic demand for high quality healthcare products in the PRC and build its portfolio companies into market sector leaders with competitive edge. Cathay has already demonstrated a strong track record of identifying high- growth potential investment opportunities in this area including: Lansen, a leading specialty pharmaceutical company focused on rheumatology and dermatology in the PRC; Haizi, a company engaged in the manufacture, marketing and sale of inositol and its by-product, di-calcium phosphate; Natural Dailyhealth, a company engaged in production and sales of plant extracts for use as key active ingredients in healthcare products; and Botai, a company engaged in collagen products.
The Group employs approximately 2,000 people across the PRC, including over 30 specialist corporate and business development staff based at the holding company's offices in Hong Kong and Shenzhen. Cathay also has a hotel investment. For more information please visit the Company's website: www.cathay-intl.com.hk.
CTI.L (CTI)